Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Deadly attack on kindergarten reported in Sudan - 2Flourishing in Retirement: Individual Accounts of Post-Profession Satisfaction
- 36 Vehicle Rental Administrations: Pick Your Ideal Ride
- 4Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- 5RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
- NASA loses contact with its Maven spacecraft orbiting Mars for the past decade
- Figure out How to Pick a Crematorium: Key Contemplations.
- Parents who delay baby's first vaccines also likely to skip measles shots
- Seven deaths possibly linked to malfunctioning glucose monitors
- Archaeologists uncover details about the Hjortspring boat's origins
- Carrying on with a Sans plastic Way of life: Individual Examinations in Maintainability
- Chicago reports first rabies-positive dog in 61 years. What we know.
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
